McIlrath & Eck’s Alnylam Pharmaceuticals ALNY Stock Holding History

McIlrath & Eck’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3	Closed	-$601	–	896
2023 Q1	$601	Buy	+3	New	+$631	﹤0.01%	868

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

McIlrath & Eck's ALNY Position: Q2 2023 in Review

McIlrath & Eck sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 3 shares — an estimated $601 sold.

McIlrath & Eck first reported a position in ALNY in Q1 2023 and held it in 1 quarter. The position peaked at $601 in Q1 2023. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

McIlrath & Eck reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
McIlrath & Eck sold 3 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $601.
McIlrath & Eck first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 1 quarter.
McIlrath & Eck's Alnylam Pharmaceuticals position peaked at $601 in Q1 2023.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on McIlrath & Eck's 13F filing for Q2 2023, filed 7 Aug 2023.